Pembrolizumab, as a PD-1 inhibitor, primarily acts within the tumor microenvironment to reinvigorate exhausted T-cells and restore localized immune responses without broadly disrupting immune homeostasis [1]. Here, PDCD1 is linked to neoplasm.